Skeletal muscle in chronic obstructive pulmonary disease

Clinical Pulmonary Medicine

Volumn 16, Issue 2, 2009, Pages 61-67

  Jackson, Abigail Susan ^a   Hopkinson, Nicholas ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Chronic obstructive pulmonary disease (COPD); Pulmonary rehabilitation; Quadriceps strength; Skeletal muscle

Indexed keywords

CORTICOSTEROID; HUMAN GROWTH HORMONE; MEGESTROL ACETATE; PREDNISOLONE; STEROID; TESTOSTERONE;

BODY COMPOSITION; BODY MASS; BREATHING MUSCLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; ELECTROSTIMULATION; GENETIC SUSCEPTIBILITY; HUMAN; HYPERCAPNIA; HYPOXIA; INFLAMMATION; MORTALITY; MUSCLE EXERCISE; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYOPATHY; PULMONARY REHABILITATION; REVIEW; SKELETAL MUSCLE; UNSPECIFIED SIDE EFFECT; WEIGHT;

EID: 67650376026     PISSN: 10680640     EISSN: None     Source Type: Journal    
DOI: 10.1097/CPM.0b013e31819b15d5     Document Type: Review

References (136)

1. Fowler JK, Godlee RJ. Diseases of the Lungs. London, UK: Longmans Green and Co; 1898.
2. Boushy SF, Adhikari PK, Sakamoto A, et al. Factors affecting prognosis in emphysema. Dis Chest. 1964;45:402-411.
3. Vandenbergh E, Van de Woestijne KP, Gyselen A. Weight changes in the terminal stages of chronic obstructive pulmonary disease. Relation to respiratory function and prognosis. Am Rev Respir Dis. 1967;95:556-566.
4. Prescott E, Almdal T, Mikkelsen KL, et al. Prognostic value of weight change in chronic obstructive pulmonary disease: results from the Copenhagen City Heart Study. Eur Respir J. 2002;20:539-544.
5. Landbo C, Prescott E, Lange P, et al. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160:1856-1861.
6. Wilson DO, Rogers RM, Wright EC, et al.; The National Institutes of Health Intermittent Positive-Pressure Breathing Trial. Body weight in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1989;139:1435-1438.
7. Engelen MP, Schols AM, Baken WC, et al. Nutritional depletion in relation to respiratory and peripheral skeletal muscle function in out-patients with COPD. Eur Respir J. 1994;7:1793-1797.
8. Schols AM, Soeters PB, Dingemans AM, et al. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis. 1993;147:1151-1156.
9. Gray-Donald K, Gibbons L, Shapiro SH, et al. Nutritional status and mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996;153:961-966.
10. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:1005-1012.
11. Marti S, Munoz X, Rios J, et al. Body weight and comorbidity predict mortality in COPD patients treated with oxygen therapy. Eur Respir J. 2006;27:689-696.
12. Chailleux E, Laaban J-P, Veale D. Prognostic value of nutritional depletion in patients with COPD treated by long-term oxygen therapy: data from the ANTADIR Observatory. Chest. 2003;123:1460-1466.
13. Cano NJ, Pichard C, Roth H, et al. C-reactive protein and body mass index predict outcome in end-stage respiratory failure. Chest. 2004;126:540-546.
14. Schols AM, Slangen J, Volovics L, et al. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1791-1797.
15. Harik-Khan RI, Fleg JL, Wise RA. Body mass index and the risk of COPD. Chest. 2002;121:370-376.
16. Mostert R, Goris A, Weling-Scheepers C, et al. Tissue depletion and health related quality of life in patients with chronic obstructive pulmonary disease. Respir Med. 2000;94:859-867.
17. Shoup R, Dalsky G, Warner S, et al. Body composition and health-related quality of life in patients with obstructive airways disease. Eur Respir J. 1997;10:1576-1580.
18. Soler-Cataluna JJ, Sanchez-Sanchez L, Martinez-Garcia MA, et al. Mid-arm muscle area is a better predictor of mortality than body mass index in COPD. Chest. 2005;128:2108-2115.
19. Marquis K, Debigare R, Lacasse Y, et al. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002; 166:809-813.
20. Schols AM, Wouters EF, Soeters PB, et al. Body composition by bioelec-trical-impedance analysis compared with deuterium dilution and skinfold anthropometry in patients with chronic obstructive pulmonary disease. Am J Clin Nutr. 1991;53:421-424.
21. Hamilton AL, Killian KJ, Summers E, et al. Muscle strength, symptom intensity, and exercise capacity in patients with cardiorespiratory disorders. Am J Respir Crit Care Med. 1995;152:2021-2031.
22. Gosselink R, Troosters T, Decramer M. Peripheral muscle weakness contributes to exercise limitation in COPD. Am J Respir Crit Care Med. 1996;153:976-980.
23. Bernard S, LeBlanc P, Whittom F, et al. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;158:629-634.
24. Engelen MP, Schols AM, Does JD, et al. Skeletal muscle weakness is associated with wasting of extremity fat-free mass but not with airflow obstruction in patients with chronic obstructive pulmonary disease. Am J Clin Nutr. 2000;71:733-738.
25. Man WD, Soliman MG, Nikoletou D, et al. Non-volitional assessment of skeletal muscle strength in patients with chronic obstructive pulmonary disease. Thorax. 2003;58:665-669.
26. Swallow EB, Reyes D, Hopkinson NS, et al. Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. Thorax. 2007;62:115-120.
27. Simpson K, Killian K, McCartney N, et al. Randomized controlled trial of weightlifting exercise in patients with chronic airflow limitation. Thorax. 1992;47:70-75.
28. Decramer M, Gosselink R, Troosters T, et al. Muscle weakness is related to utilization of health care resources in COPD patients. Eur Respir J. 1997; 10:417-423.
29. Coronell C, Orozco-Levi M, Mendez R, et al. Relevance of assessing quadriceps endurance in patients with COPD. Eur Respir J. 2004;24:129-136.
30. Swallow EB, Gosker HR, Ward KA, et al. A novel technique for nonvoli-tional assessment of quadriceps muscle endurance in humans. J Appl Physiol. 2007;103:739-746.
31. Rochester DF, Braun NM. Determinants of maximal inspiratory pressure in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1985;132:42-47.
32. Mulvey DA, Elliott MW, Koulouris NG, et al. Sniff esophageal and nasopharyngeal pressures and maximal relaxation rates in patients with respiratory dysfunction. Am Rev Respir Dis. 1991;143:950-953.
33. Polkey MI, Kyroussis D, Hamnegard CH, et al. Diaphragm strength in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996; 154:1310-1317.
34. Braun NM, Arora NS, Rochester DF. Force-length relationship of the normal human diaphragm. J Appl Physiol. 1982;53:405-412.
35. Similowski T, Yan S, Gauthier AP, et al. Contractile properties of the human diaphragm during chronic hyperinflation. N Engl J Med. 1991;325:917-923.
36. Orozco-Levi M, Gea J, Lloreta JL, et al. Subcellular adaptation of the human diaphragm in chronic obstructive pulmonary disease. Eur Respir J. 1999; 13:371-378.
37. O'Donnell DE, Webb KA, Bertley JC, et al. Mechanisms of relief of exertional breathlessness following unilateral bullectomy and lung volume reduction surgery in emphysema. Chest. 1996;110:18-27.
38. Hopkinson NS, Toma TP, Hansell DM, et al. Effect of bronchoscopic lung volume reduction on dynamic hyperinflation and exercise in emphysema. Am J Respir Crit Care Med. 2005;171:453-460.
39. Johnson BD, Babcock MA, Suman OE, et al. Exercise-induced diaphragmatic fatigue in healthy humans. J Physiol. 1993;460:385-405.
40. Luo YM, Hart N, Mustfa N, et al. Effect of diaphragm fatigue on neural respiratory drive. J Appl Physiol. 2001;90:1691-1699.
41. Kyroussis D, Mills GH, Polkey MI, et al. Abdominal muscle fatigue after maximal ventilation in humans. J Appl Physiol. 1996;81:1477-1483.
42. Polkey MI, Kyroussis D, Hamnegard CH, et al. Diaphragm performance during maximal voluntary ventilation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1997;155:642-648.
43. Polkey MI, Kyroussis D, Keilty SE, et al. Exhaustive treadmill exercise does not reduce twitch transdiaphragmatic pressure in patients with COPD. Am J Respir Crit Care Med. 1995;152:959-964.
44. Mador MJ, Kufel TJ, Pineda LA, et al. Diaphragmatic fatigue and high-intensity exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:118-123.
45. Levine S, Kaiser L, Leferovich J, et al. Cellular adaptations in the diaphragm in chronic obstructive pulmonary disease. N Engl J Med. 1997;337:1799-1806.
46. Edwards RH, Hyde S. Methods of measuring muscle strength and fatigue. Physiotherapy. 1977;63:51-55.
47. Polkey MI, Kyroussis D, Hamnegard CH, et al. Quadriceps strength and fatigue assessed by magnetic stimulation of the femoral nerve in man. Muscle Nerve. 1996;19:549-555.
48. Mador MJ, Deniz O, Aggarwal A, et al. Quadriceps fatigability after single muscle exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;168:102-108.
49. Degens H, Sanchez Horneros JM, Hopman MT. Acute hypoxia limits endurance but does not affect muscle contractile properties. Muscle Nerve. 2006;33:532-537.
50. Zattara-Hartmann MC, Badier M, Guillot C, et al. Maximal force and endurance to fatigue of respiratory and skeletal muscles in chronic hypox-emic patients: the effects of oxygen breathing. Muscle Nerve. 1995;18:495-502.
51. Black LF, Hyatt RE. Maximal respiratory pressures: normal values and relationship to age and sex. Am Rev Respir Dis. 1969;99:696-702.
52. Heritier F, Rahm F, Pasche P, et al. Sniff nasal inspiratory pressure. A noninvasive assessment of inspiratory muscle strength. Am J Respir Crit Care Med. 1994;150:1678-1683.
53. Uldry C, Fitting JW. Maximal values of sniff nasal inspiratory pressure in healthy subjects. Thorax. 1995;50:371-375.
54. Steier J, Kaul S, Seymour J, et al. The value of multiple tests of respiratory muscle strength. Thorax. 2007;62:975-980.
55. Uldry C, Janssens JP, de Muralt B, et al. Sniff nasal inspiratory pressure in patients with chronic obstructive pulmonary disease. Eur Respir J. 1997;10: 1292-1296.
56. Laroche CM, Mier AK, Moxham J, et al. The value of sniff esophageal pressures in the assessment of global inspiratory muscle strength. Am Rev Respir Dis. 1988;138:598-603.
57. Man WD, Kyroussis D, Fleming TA, et al. Cough gastric pressure and maximum expiratory mouth pressure in humans. Am J Respir Crit Care Med. 2003;168:714-717.
58. Polkey MI, Luo Y, Guleria R, et al. Functional magnetic stimulation of the abdominal muscles in humans. Am J Respir Crit Care Med. 1999;160:513-522.
59. Miller JM, Moxham J, Green M. The maximal sniff in the assessment of diaphragm function in man. Clin Sci (Lond). 1985;69:91-96.
60. Polkey MI, Green M, Moxham J. Measurement of respiratory muscle strength. Thorax. 1995;50:1131-1135.
61. American Thoracic Society/European Respiratory Society. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. A statement of the American Thoracic Society and European Respiratory Society. Am J Respir Crit Care Med. 1999;159:S1-S40.
62. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. A statement of the American Thoracic Society and European Respiratory Society. Am J Respir Crit Care Med. 1999;159:S1-S40.
63. Hopkinson NS, Nickol AH, Payne J, et al. Angiotensin converting enzyme genotype and strength in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170:395-399.
64. Gea J, Orozco-Levi M, Barreiro E, et al. Structural and functional changes in the skeletal muscles of COPD patients: the "compartments" theory. Monaldi Arch Chest Dis. 2001;56:214-224.
65. Jobin J, Maltais F, Doyon JF, et al. Chronic obstructive pulmonary disease: capillarity and fiber-type characteristics of skeletal muscle. J Cardiopulm Rehabil. 1998;18:432-437.
66. Jakobsson P, Jorfeldt L, Brundin A. Skeletal muscle metabolites and fibre types in patients with advanced chronic obstructive pulmonary disease (COPD), with and without chronic respiratory failure. Eur Respir J. 1990; 3:192-196.
67. Gosker HR, Kubat B, Schaart G, et al. Myopathological features in skeletal muscle of patients with chronic obstructive pulmonary disease. Eur Respir J. 2003;22:280-285.
68. Maltais F, Jobin J, Sullivan MJ, et al. Metabolic and hemodynamic responses of lower limb during exercise in patients with COPD. J Appl Physiol. 1998;84:1573-1580.
69. Richardson RS, Leek BT, Gavin TP, et al. Reduced mechanical efficiency in chronic obstructive pulmonary disease but normal peak VO2 with small muscle mass exercise. Am J Respir Crit Care Med. 2004;169:89-96.
70. Appell HJ. Muscular atrophy following immobilization: a review. Sports Med. 1990;10:42-58.
71. Harris ML, Polkey MI, Bath PM, et al. Quadriceps muscle weakness following acute hemiplegic stroke. Clin Rehabil. 2001;15:274-281.
72. Kortebein P, Ferrando A, Lombeida J, et al. Effect of 10 days of bed rest on skeletal muscle in healthy older adults. JAMA. 2007;297:1772-1774.
73. Sandri M, Lin J, Handschin C, et al. PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci USA. 2006;103:16260-16265.
74. Sandri M, Sandri C, Gilbert A, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 2004;117:399-412.
75. Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59:574-580.
76. Reid MB, Lannergren J, Westerblad H. Respiratory and limb muscle weakness induced by tumor necrosis factor-alpha: involvement of muscle myofilaments. Am JRespir Crit Care Med. 2002;166:479-484.
77. Eid AA, Ionescu AA, Nixon LS, et al. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:1414-1418.
78. Schols AM, Creutzberg EC, Buurman WA, et al. Plasma leptin is related to proinflammatory status and dietary intake in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160:1220-1226.
79. Barreiro E, Schols AM, Polkey MI, et al. Cytokine profile in quadriceps muscles of patients with severe COPD. Thorax. 2008;63:100-107.
80. Howald H, Pette D, Simoneau JA, et al. Effect of chronic hypoxia on muscle enzyme activities. Int J Sports Med. 1990;11(suppl 1):S10-S14.
81. Couillard A, Maltais F, Saey D, et al. Exercise-induced quadriceps oxidative stress and peripheral muscle dysfunction in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;167:1664-1669.
82. Koechlin C, Couillard A, Simar D, et al. Does oxidative stress alter quadriceps endurance in chronic obstructive pulmonary disease? Am J Respir Crit Care Med. 2004;169:1022-1027.
83. Rabinovich RA, Bastos R, Ardite E, et al. Mitochondrial dysfunction in COPD patients with low body mass index (epub). Eur Respir J. 2007;29: 643-650.
84. Maltais F, Simard AA, Simard C, et al. Oxidative capacity of the skeletal muscle and lactic acid kinetics during exercise in normal subjects and in patients with COPD. Am J Respir Crit Care Med. 1996;153:288-293.
85. Vianna LG, Koulouris N, Lanigan C, et al. Effect of acute hypercapnia on limb muscle contractility in humans. J Appl Physiol. 1990;69:1486-1493.
86. Schonhofer B, Zimmermann C, Abramek P, et al. Non-invasive mechanical ventilation improves walking distance but not quadriceps strength in chronic respiratory failure. Respir Med. 2003;97:818-824.
87. Schonhofer B, Polkey MI, Suchi S, et al. Effect of home mechanical ventilation on inspiratory muscle strength in COPD. Chest. 2006;130:1834-1838.
88. Viires N, Pavlovic D, Pariente R, et al. Effects of steroids on diaphragmatic function in rats. Am Rev Respir Dis. 1990;142:34-38.
89. Decramer M, de Bock V, Dom R Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996;153:1958-1964.
90. Hopkinson NS, Man WD, Dayer MJ, et al. Acute effect of oral steroids on muscle function in chronic obstructive pulmonary disease. Eur Respir J. 2004;24:137-142.
91. Pescatello LS, Kostek MA, Gordish-Dressman H, et al. ACE ID genotype and the muscle strength and size response to unilateral resistance training. Med Sci Sports Exerc. 2006;38:1074-1081.
92. Ahmetov II, Mozhayskaya IA, Flavell DM, et al. PPARalpha gene variation and physical performance in Russian athletes. Eur J Appl Physiol. 2006;97: 103-108.
93. Kostek MC, Delmonico MJ, Reichel JB, et al. Muscle strength response to strength training is influenced by insulin-like growth factor 1 genotype in older adults. J Appl Physiol. 2005;98:2147-2154.
94. Clarkson PM, Devaney JM, Gordish-Dressman H, et al. ACTN3 genotype is associated with increases in muscle strength in response to resistance training in women. J Appl Physiol. 2005;99:154-163.
95. Hopkinson NS, Li KW, Kehoe A, et al. Vitamin D receptor genotypes influence quadriceps strength in chronic obstructive pulmonary disease. Am J Clin Nutr. 2008;87:385-390.
96. Hopkinson NS, Eleftheriou KI, Payne J, et al. +9/ + 9 homozygosity of the bradykinin receptor gene polymorphism is associated with reduced fat-free mass in chronic obstructive pulmonary disease. Am J Clin Nutr. 2006;83: 912-917.
97. Spruit MA, Gosselink R, Troosters T, et al. Muscle force during an acute exacerbation in hospitalized patients with COPD and its relationship with CXCL8 and IGF-I. Thorax 2003;58:752-756.
98. Saudny-Unterberger H, Martin JG, Gray-Donald K. Impact of nutritional support on functional status during an acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1997;156:794-799.
99. Pitta F, Troosters T, Probst VS, et al. Quantifying physical activity in daily life with questionnaires and motion sensors in COPD. Eur Respir J. 2006;27:1040-1055.
100. Hopkinson NS, Tennant RC, Dayer MJ, et al. A prospective study of decline in fat-free mass and skeletal muscle strength in chronic obstructive pulmonary disease. Respir Res. 2007;8:25.
101. Nici L, Donner C, Wouters E, et al. American Thoracic Society/European Respiratory Society Statement on pulmonary rehabilitation. Am J Respir Crit Care Med. 2006;173:1390-1413.
102. Griffiths TL, Burr ML, Campbell IA, et al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomized controlled trial. Lancet. 2000;355:362-368.
103. Griffiths TL, Phillips CJ, Davies S, et al. Cost effectiveness of an outpatient multidisciplinary pulmonary rehabilitation programme. Thorax. 2001;56: 779-784.
104. Golmohammadi K, Jacobs P, Sin DD. Economic evaluation of a community-based pulmonary rehabilitation program for chronic obstructive pulmonary disease. Lung. 2004;182:187-196.
105. California Pulmonary Rehabilitation Collaborative Group. Effects of pulmonary rehabilitation on dyspnea, quality of life, and healthcare costs in California. J Cardiopulm Rehabil. 2004;24:52-62.
106. O'Donnell DE, McGuire M, Samis L, et al. General exercise training improves ventilatory and peripheral muscle strength and endurance in chronic airflow limitation. Am J Respir Crit Care Med. 1998;157:1489-497.
107. Ries AL, Kaplan RM, Limberg TM, et al. Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med. 1995;122:823-832.
108. Troosters T, Gosselink R, Decramer M. Short- and long-term effects of outpatient rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. Am J Med. 2000;109:207-212.
109. Murphy N, Bell C, Costello RW. Extending a home from hospital care programme for COPD exacerbations to include pulmonary rehabilitation. Respir Med. 2005;99:1297-1302.
110. From the Global Strategy for the diagnosis, management, and prevention of COPD, Global initiative for chronic obstructive lung disease (GOLD) 2007. Available at: http://www.goldcopd.org.
111. Efthimiou J, Fleming J, Gomes C, et al. The effect of supplementary oral nutrition in poorly nourished patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1988;137:1075-1082.
112. Rogers RM, Donahoe M, Costantino J. Physiologic effects of oral supplemental feeding in malnourished patients with chronic obstructive pulmonary disease: a randomized control study. Am Rev Respir Dis. 1992;146:1511-1517.
113. Whittaker JS, Ryan CF, Buckley PA, et al. The effects of refeeding on peripheral and respiratory muscle function in malnourished chronic obstructive pulmonary disease patients. Am Rev Respir Dis. 1990;142:283-288.
114. Ferreira IM, Brooks D, Lacasse Y, et al. Nutritional supplementation for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005:CD000998.
115. Branch JD. Effect of creatine supplementation on body composition and performance: a meta-analysis. Int J Sport Nutr Exerc Metab. 2003;13:198 -226.
116. Fuld JP, Kilduff LP, Neder JA, et al. Creatine supplementation during pulmonary rehabilitation in chronic obstructive pulmonary disease. Thorax. 2005;60:531-537.
117. Duchateau J, Hainaut K. Training effects of sub-maximal electrostimulation in a human muscle. Med Sci Sports Exerc. 1988;20:99-104.
118. Hainaut K, Duchateau J. Neuromuscular electrical stimulation and voluntary exercise. Sports Med. 1992;14:100-113.
119. Maillefert JF, Eicher JC, Walker P, et al. Effects of low-frequency electrical stimulation of quadriceps and calf muscles in patients with chronic heart failure. J Cardiopulm Rehabil. 1998;18:277-282.
120. Nuhr MJ, Pette D, Berger R, et al. Beneficial effects of chronic low-frequency stimulation of thigh muscles in patients with advanced chronic heart failure. Eur Heart J. 2004;25:136 -143.
121. Bourjeily-Habr G, Rochester CL, Palermo F, et al. Randomized controlled trial of transcutaneous electrical muscle stimulation of the lower extremities in patients with chronic obstructive pulmonary disease. Thorax. 2002;57: 1045-1049.
122. Vivodtzev I, Pepin JL, Vottero G, et al. Improvement in quadriceps strength and dyspnea in daily tasks after 1 month of electrical stimulation in severely deconditioned and malnourished COPD. Chest. 2006;129:1540-1548.
123. Hoffman AR, Kuntze JE, Baptista J, et al. Growth hormone (GH) replacement therapy in adult-onset GH deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89:2048-2056.
124. Papadakis MA, Grady D, Black D, et al. Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med. 1996;124:708-716.
125. Hennessey JV, Chromiak JA, DellaVentura S, et al. Growth hormone administration and exercise effects on muscle fiber type and diameter in moderately frail older people. J Am Geriatr Soc. 2001;49:852-858.
126. Taaffe DR, Pruitt L, Reim J, et al. Effect of recombinant human growth hormone on the muscle strength response to resistance exercise in elderly men. J Clin Endocrinol Metab. 1994;79:1361-1366.
127. Burdet L, de Muralt B, Schutz Y, et al. Administration of growth hormone to underweight patients with chronic obstructive pulmonary disease: a prospective, randomized, controlled study. Am J Respir Crit Care Med. 1997;156:1800-1806.
128. Mulligan T, Frick MF, Zuraw QC, et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60:762-769.
129. Svartberg J, Aasebo U, Hjalmarsen A, et al. Testosterone treatment improves body composition and sexual function in men with COPD, in a 6-month randomized controlled trial. Respir Med. 2004;98:906-913.
130. Creutzberg EC, Wouters EF, Mostert R, et al. A role for anabolic steroids in the rehabilitation of patients with COPD? A double-blind, placebo-controlled, randomized trial. Chest. 2003;124:1733-1742.
131. Yeh SS, DeGuzman B, Kramer T. Reversal of COPD-associated weight loss using the anabolic agent oxandrolone. Chest. 2002;122:421-428.
132. Ferreira IM, Verreschi IT, Nery LE, et al. The influence of 6 months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients. Chest. 1998;114:19-28.
133. Casaburi R, Bhasin S, Cosentino L, et al. Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170:870-878.
134. Lambert CP, Sullivan DH, Freeling SA, et al. Effects of testosterone replacement and/or resistance exercise on the composition of megestrol acetate stimulated weight gain in elderly men: a randomized controlled trial. J Clin Endocrinol Metab. 2002;87:2100-2106.
135. Sullivan DH, Roberson PK, Smith ES, et al. Effects of muscle strength training and megestrol acetate on strength, muscle mass, and function in frail older people. J Am Geriatr Soc. 2007;55:20-28.
136. Weisberg J, Wanger J, Olson J, et al. Megestrol acetate stimulates weight gain and ventilation in underweight COPD patients. Chest. 2002;121:1070-1078.